<scp>PIONEER REAL</scp> Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice
In routine clinical practice, HbA<sub>1c</sub> and bodyweight were significantly reduced from baseline in adults initiating oral semaglutide, including those aged ≥75 years, with no new safety concerns.
Authors
- Uffe Christian Braae (ORCID: https://orcid.org/0000-0002-2743-4584)
- Hanan Amadid (ORCID: https://orcid.org/0000-0001-5759-4960)
- Rimei Nishimura (ORCID: https://orcid.org/0000-0001-6222-119X)
- Yoshiyuki Hamamoto (ORCID: https://orcid.org/0000-0002-1938-7394)
- Ryo Suzuki (ORCID: https://orcid.org/0000-0002-2965-6906)
- Daisuke Yabe (ORCID: https://orcid.org/0000-0002-5334-7687)
- Atheline Major‐Pedersen (ORCID: https://orcid.org/0000-0002-1755-630X)
- Yasuo Terauchi (ORCID: https://orcid.org/0000-0002-8872-3697)
- Daiji Kawanami (ORCID: https://orcid.org/0000-0002-8926-4701)
Institutions
- Jikei University School of Medicine (JP)
- Tokyo Medical University (JP)
- Novo Nordisk (Denmark) (DK)
- Kyoto University (JP)
- Kansai Electric Power (Japan) (JP)
- Fukuoka University (JP)
- Kansai Electric Power Hospital (JP)
- Gifu University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-08-22
- DOI
- https://doi.org/10.1111/jdi.14291
- Citations
- 18
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.44
Funders
- Eli Lilly and Company
- Novo Nordisk
- Eli Lilly Japan
- Novo Nordisk Pharma